Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068697 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3067445 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3072155 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3068404 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL619051 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL22117137 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3083251 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3064622 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL3066992 | 1.00 | NOS1 (0.30) | NOS1NOS2 | |
| SCHEMBL17672286 | 1.00 | NOS1 (0.30) | NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119066270-B | Barley crop planting recommendation method | 陇东学院 | 2025-03-25 | — | — | CN | disclosed |
| CN-110230897-B | Dry-heat type single-pump geothermal system and construction method thereof | 河南省昌通新能源有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119066270-A | Barley crop planting recommendation method | 陇东学院 | 2024-12-03 | — | — | CN | disclosed |
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | CORCEPT THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CRH, MC2R, NR3C2 | NOS1 3841/4885NOS2 3480/4885 |
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | NR3C2, MC2R, NR3C1 | NOS1 3797/4885NOS2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.